Nov 30, 2022 / 08:30PM GMT
Ted Tenthoff - Piper Sandler Companies - Analyst
My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. Before I begin, I'm required to draw your attention to certain disclosures regarding the relationship between Piper and Aravive that are posted at the back of the room and also at the registration desk.
Aravive is developing batiraxcept, a high affinity GAS6 decoy receptor. The company is conducting a Phase 3 trial with paclitaxel in ovarian cancer with topline data next year, and also Phase 2 combo studies with Cabometyx in kidney cancer and with gem-Abraxane in pancreatic cancer.
Here to present from the company is Aravive's CEO, Gail McIntyre.
Gail McIntyre - Aravive, Inc. - CEO & Board Director
Thank you, Ted. Thanks for inviting us. I will be making forward-looking statements. So, the typical cautions apply here. As Ted said, we have a lead program called batiraxcept and it is in late-stage clinical trials. We are very different than other companies in that we are the only company targeting GAS6. GAS6 is the sole
Aravive Inc at Piper Sandler Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers